Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
The US Food and Drug Administration (FDA) has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) in leukocyte adhesion deficiency type I …
Post
-
-
Novartis to acquire Excellergy for $2bn upfront
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) …
-
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim …
-
Corcept’s first-in-class ovarian cancer drug gains FDA approval
Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three …
-
FDA opens door to feedback on ‘unclear’ national priority voucher pathway
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National …
-
Cognito Therapeutics and Ochsner partner for new brain health approaches
US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new …
-
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody …
-
The Most Favored Nation Policy: early insights into Europe’s response
On 12 May 2025, US President Donald Trump signed an executive order directing the US Department of Health and Human …
-
UCB banks on Georgia for $2bn biologics manufacturing facility
UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and …
-
Improving early detection and treatment of liver cancer
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour …
-
MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement
MSD will buy cancer specialist Terns Pharmaceuticals in a deal worth $6.7bn, as the drugmaker continues its string of multibillion-dollar …
-
Researchers become scientific tastemakers by handing more R&D to autonomous labs
Pharmaceutical R&D is falling increasingly to artificial intelligence (AI)-guided autonomous laboratories, and the people behind them say the role of …
-
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause …
-
MSD and Quotient collaborate on IBD drug targets
Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory …
-
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition
On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an …
